Home » Stocks » BTAI

BioXcel Therapeutics, Inc. (BTAI)

Stock Price: $47.32 USD -0.75 (-1.56%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $47.54 +0.22 (0.47%) Jan 22, 7:56 PM
Market Cap 1.15B
Revenue (ttm) n/a
Net Income (ttm) -69.36M
Shares Out 23.05M
EPS (ttm) -3.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $47.32
Previous Close $48.07
Change ($) -0.75
Change (%) -1.56%
Day's Open 47.50
Day's Range 46.65 - 47.92
Day's Volume 473,866
52-Week Range 14.79 - 64.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 1 week ago

High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first...

Other stocks mentioned: RADA, TDOC, XPEV
Seeking Alpha - 3 weeks ago

BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead ...

GlobeNewsWire - 1 month ago

Company to present corporate update and plans for 2021

GlobeNewsWire - 1 month ago

Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic s...

GlobeNewsWire - 2 months ago

NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intellig...

Seeking Alpha - 2 months ago

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021

GlobeNewsWire - 2 months ago

Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”)

GlobeNewsWire - 2 months ago

Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)

GlobeNewsWire - 2 months ago

NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...

GlobeNewsWire - 2 months ago

Fifth potential indication for BXCL501, an orally dissolving thin film Fifth potential indication for BXCL501, an orally dissolving thin film

Seeking Alpha - 2 months ago

BioXcel product candidates use the 505(b)(2) approval pathway. Successful pivotal trials for two indications in acute agitation.

Seeking Alpha - 3 months ago

Today, we look at a promising CNS play called BioXcel Therapeutics. The shares have lost more than a third from their pre-secondary offering highs.

24/7 Wall Street - 3 months ago

With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at wha...

Other stocks mentioned: CI, HAE, HZNP, VRTX
Seeking Alpha - 3 months ago

In 2020, the central nervous system (CNS) market has largely failed to keep up with $IBB.

GlobeNewsWire - 4 months ago

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intellige...

Seeking Alpha - 5 months ago

BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript

The Motley Fool - 5 months ago

Investors were not impressed with the company's latest quarterly update.

GlobeNewsWire - 5 months ago

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligen...

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announce...

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announce...

The Motley Fool - 6 months ago

The company reported positive results from two pivotal clinical trials.

Investors Business Daily - 6 months ago

Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high. The post Biox...

GlobeNewsWire - 6 months ago

Highly statistically significant improvements in PEC score observed vs. placebo (p

GlobeNewsWire - 6 months ago

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation Company providing BXCL501 to evaluate its activ...

GlobeNewsWire - 6 months ago

Patent is expected to extend IP protection until 2039 Patent is expected to extend IP protection until 2039

GlobeNewsWire - 6 months ago

Will lead global clinical development strategy and medical affairs for the Company’s neuroscience programs Will lead global clinical development strategy and medical affairs for the Company’s ...

The Motley Fool - 7 months ago

Here's why investors shouldn't bet on these two companies long-term, at least not yet.

Other stocks mentioned: CRON
GlobeNewsWire - 7 months ago

Former Allergan Commercial Head to lead commercialization efforts for BXCL501 across multiple neuropsychiatric disorders Former Allergan Commercial Head to lead commercialization efforts for B...

GlobeNewsWire - 7 months ago

NEW HAVEN, Conn., June 15, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intell...

24/7 Wall Street - 7 months ago

The 2020 year is practically halfway done, and this has really been the year of the biotech.

Other stocks mentioned: ACAD, BIIB, CRTX, ITCI, NBIX, SAGE, ZYNE
GlobeNewsWire - 7 months ago

Topline results expected in the first quarter of 2021 Topline results expected in the first quarter of 2021

GlobeNewsWire - 8 months ago

Topline results, expected in July of 2020, are intended to support a New Drug Application filing Topline results, expected in July of 2020, are intended to support a New Drug Application filing

Seeking Alpha - 8 months ago

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

 Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020

The Motley Fool - 9 months ago

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BCYC, IGMS
Benzinga - 9 months ago

BioXcel Therapeutics (NASDAQ: BTAI) founder and CEO Dr. Mehta Vimal spoke with Benzinga about its BXCL-501 drug candidate for agitation in Alzheimer's patients — and how it relates to wearable...

GlobeNewsWire - 10 months ago

More than one-third of the SERENITY I & II patients have been dosed, including over 100 bipolar patients

The Motley Fool - 10 months ago

Unlike much of the market, BioXcel Therapeutics is actually up year to date.

Seeking Alpha - 10 months ago

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia

The Motley Fool - 11 months ago

Shares tumble after the company announces that it is raising capital.

The Motley Fool - 11 months ago

Can these soaring biotech stocks keep climbing?

Other stocks mentioned: ADAP, AVXL
24/7 Wall Street - 11 months ago

One reason that investors continue to do business with full-service brokerage firms is they generate researched and studied investment ideas.

Other stocks mentioned: RARE, VKTX
GlobeNewsWire - 11 months ago

Company is preparing to initiate Phase 1b/2 RELEASE trial Company is preparing to initiate Phase 1b/2 RELEASE trial

Seeking Alpha - 11 months ago

BioXcel Therapeutics: AI-Focused Biopharmaceutical Player For 2020

InvestorPlace - 1 year ago

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

Other stocks mentioned: ATEC, BDSI, FOLD, GERN, INO, INSM
GlobeNewsWire - 1 year ago

Topline results expected in mid-2020 Topline results expected in mid-2020

GlobeNewsWire - 1 year ago

BXCL701 may improve patient response when combined with checkpoint inhibitors or re-sensitize patients who have failed checkpoint therapy BXCL701 may improve patient response when combined wit...

About BTAI

BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaborat... [Read more...]

Industry
Biotechnology
IPO Date
Mar 8, 2018
CEO
Vimal Mehta
Employees
40
Stock Exchange
NASDAQ
Ticker Symbol
BTAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price forecast is 112.00, which is an increase of 136.69% from the latest price.

Price Target
$112.00
(136.69% upside)
Analyst Consensus: Strong Buy